Source: Semafor
Jensen Huang's dominance in AI chips has created a single point of failure for biotech companies relying on Nvidia's GPUs for drug discovery. Geopolitical restrictions are now forcing them to choose between US technology monopolies and regulated alternatives in other markets. Insilico Medicine's reliance on UAE data centers shows how biotech globalization has become hostage to semiconductor nationalism. Companies like Zhavoronkov's face either accepting US tech dominance or accepting performance tradeoffs and increased compliance burdens in their operating jurisdictions. The cost extends beyond slower drug discovery: it's the stratification of innovation capacity by geography and access, potentially concentrating cutting-edge therapeutics development among well-capitalized Western firms while others operate with degraded capabilities.